Inclusive Packaging for a Medication Line with Low Literacy Users
A pharmaceutical company is redesigning packaging for a line of three chronic-use medications taken by adults with varying literacy levels. Current packaging uses 8-pt text, a busy background pattern, and distinguishes the three dosages only by small color differences in the border. Field reports show dosage mix-ups, especially among users over 65 and users with low literacy. Regulatory requirements mandate the active ingredient name, dosage, and a warning block, but do not specify typography, layout, or color. The design team proposes a full redesign with larger type, dosage-differentiated shapes, and pictorial instructions. The regulatory affairs department warns that any layout change requires revalidation and that pictorials may not be permitted without approval. The launch date is fixed in five months.
1. What design strategy best balances safety, regulation, and timeline?
Read the worked answer
Adopt a two-track strategy. Track one: immediate, low-risk changes that do not alter regulated content - increase type size, increase contrast, simplify the background, and add redundant dosage differentiation through shape and large numerals, since these are layout and typography changes within the existing approved text. Track two: submit pictorial instructions and any structural changes for regulatory approval in parallel, so they can be added in a later revision if approved. This prioritizes the documented failure mode (dosage mix-up) with changes that address it directly and quickly, while respecting the revalidation constraint. The reasoning is to separate changes by regulatory risk and by their effect on the identified error, rather than treating the redesign as an all-or-nothing package tied to a fixed launch date.
2. How would you justify the dosage differentiation approach to a skeptical regulatory reviewer?
Read the worked answer
Justify it by linking each design element to a specific error mechanism. The current border color differences fail because color discrimination declines with age and because the differences are small; shape and large numerals provide redundant cues that do not depend on fine color perception. Present evidence: a comparison of the current and proposed packs under simulated low-vision and low-light conditions, and a comprehension check with representative users on whether they can distinguish dosages at a glance. Emphasize that no regulated text is removed or altered, so the change is additive and does not affect the approved content. Offer a validation protocol so the reviewer sees the change is controlled and testable rather than an uncontrolled aesthetic revision.